Wells Fargo & Company Biofrontera Inc. Transaction History

Wells Fargo & Company

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 15, 2023	BUY	$0.4 - $0.65 $2 - $3	5 Added 4.1%	127 $0
Q1 2023 May 12, 2023	BUY	$0.56 - $1.02 $1 - $2	2 Added 1.67%	122 $0
Q4 2022 Feb 13, 2023	BUY	$0.77 - $24.8 $13 - $421	17 Added 16.5%	120 $0
Q3 2022 Nov 14, 2022	BUY	$0.82 - $41.8 $36 - $1,880	45 Added 77.59%	103 $0
Q2 2022 Aug 12, 2022	BUY	$37.2 - $99.2 $148 - $396	4 Added 7.41%	58 $0
Q1 2022 May 16, 2022	BUY	$45.0 - $138.4 $1,395 - $4,290	31 Added 134.78%	54 $0
Q4 2021 Feb 14, 2022	BUY	$49.4 - $263.4 $1,136 - $6,058	23 New	23 $0

Ticker BFRI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 23,551,000
Market Cap $22.6M
Description
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for phot...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.